Scientific Evaluation of A Unani Pharmacopoeia-Based Formulation on BPH in Animal Model
Mohammad Shujauddin¹, Shamshad Alam², Sumbul Rehman³, Murad Ahmad⁴

¹Dr. Mohammad Shujauddin, Research Scholar, Department of Ilmul Advia, Ajmal Khan Tibbia College, Faculty of Unani Medicine, AMU, Aligarh (UP), India.

²Shamshad Alam, Assistant Professor, Department of Ilmul Advia, Ajmal Khan Tibbia College, Faculty of Unani Medicine, AMU, Aligarh (UP), India.

³Sumbul Rehman, Assistant Professor, Department of Ilmul Advia, Ajmal Khan Tibbia College, Faculty of Unani Medicine, AMU, Aligarh (UP), India.

⁴Murad Ahmad, Assistant professor, Department of Pathology, Jawahar Lal Nehru Medical College, AMU, Aligarh (UP), India.

Manuscript received on 10 September 2023 | Revised Manuscript received on 13 October 2023 | Manuscript Accepted on 15 November 2023 | Manuscript published on 30 November 2023 | PP: 1-8 | Volume-4 Issue-1, November 2023 | Retrieval Number: 100.1/ijpmh.A1032114123 | DOI: 10.54105/ijpmh.A1032.114123

Open Access | Ethics and Policies | Cite | Zenodo | Indexing and Abstracting
© The Authors. Published by Lattice Science Publication (LSP). This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Abstract: BPH (Benign prostatic hyperplasia) is a common problem of the prostate gland that affects elderly men with age and is a significant cause of lower urinary tract symptoms (LUTS) like urgency of urination, frequency of micturition, dysuria, nocturia, dribbling, and burning of urine. If left untreated, the condition can lead to severe urinary retention, recurrent UTI, and, in severe cases, renal failure, etc. Alpha-blockers and 5-alpha reductase inhibitors (5-ARIs) are two main classes of drugs that are used in conventional therapy to treat BPH. These phytochemical therapies are highly effective, but standard control methods also have unfavourable side effects. Conversely, evidence, though limited, has shown that alternative medicines are safer and have the potential to improve LUTS and quality of life, in addition to improving sexual dysfunction in patients with BPH. The purpose of this study is to assess the efficacy of 50% hydroalcoholic UPBF extract on BPH in TP-induced rats, and to compare the effects of the drug between the treated and untreated groups. The experimental design for anti-BPH activity was conducted according to the Bhavin model. 48 Wistar rats were divided into six groups, with eight rats in each group. Group 1, plane control (untreated rats), group 2, negative control (treated with TP 5 mg/kg), group 3, negative control (treated with TP+ finasteride 1 mg/kg), and groups 4,5 and 6 served as tests controls (A, B, and C) treated with TP+ UPBF extract 100 mg/kg, 150 mg/kg, and 200 mg/kg as low, medium, and high doses, respectively. BPH was induced in rats by administration of testosterone propionate (TP) in arachis oil, and treatment was done orally with a standard drug (finasteride) and a test drug (UPBF) once a day for 28 consecutive days. Before and after initiating the study, each rat was weighed and documented. After 28 days, blood samples were collected and the prostate gland was examined under light anaesthesia. The study’s parameters were assessed, including prostate weight, prostate-to-body weight ratio, histopathological investigation of the prostate, percentage of inhibition, percentage of recovery, and determination of ST and STP levels. Data from the results were expressed as the mean ± standard error of the mean (SEM). Evaluation between group results was carried out with the oneway ANOVA test, followed by Tukey’s test, and the significant value of p was <0.05. Both histopathological and biochemical parameter results showed substantial improvements in rats treated with finasteride and UPBF extract at a dose of 200 mg/kg (p<0.001). In addition, ST and STP levels showed a significant reduction compared to the BPH group. It can be concluded from the findings of both biochemical and histopathological parameters that the test drug (UPBF) exhibits significant effects against TP-induced BPH in rats. The findings suggested that the test drug can be used independently in the management of BPH as well as for lower urinary tract symptoms.

Keywords: Waram-e-Gudda-i-Madhi, Insidad-e-Majra-i-Mathana, UFBF on BPH, Tribulus terrestris in the Unani system, benign prostatic hyperplasia, lower urinary tract symptoms (LUTS).
Scope of the Article: Chronic Diseases